{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:59:03Z","timestamp":1793804343689,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.diabres.2025.112205","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:35:49Z","timestamp":1745678149000},"page":"112205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study"],"prefix":"10.1016","volume":"224","author":[{"given":"Tien-Hsing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Hsiung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-713X","authenticated-orcid":false,"given":"Ming-Lung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9348-8153","authenticated-orcid":false,"given":"Ming-Shyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Shin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ju","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhih-Wei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0721-1332","authenticated-orcid":false,"given":"Ning-I","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jui","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-4734","authenticated-orcid":false,"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diabres.2025.112205_b0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"issue":"3 Suppl 1","key":"10.1016\/j.diabres.2025.112205_b0010","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal data system 2018 annual data report: Epidemiology of kidney disease in the United States","volume":"73","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2025.112205_b0015","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.112205_b0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11892-019-1133-6","article-title":"The global burden of diabetic kidney disease: Time, trends, and gender gaps","volume":"19","author":"Thomas","year":"2019","journal-title":"Curr Diab Rep"},{"issue":"7","key":"10.1016\/j.diabres.2025.112205_b0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00592-018-1142-y","article-title":"Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes","volume":"55","author":"Giorda","year":"2018","journal-title":"Acta Diabetol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112205_b0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2025.112205_b0035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2025.112205_b0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112205_b0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2025.112205_b0050","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular outcomes, and Mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2025.112205_b0055","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE Trial Investigators. Canagliflozin and Renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2025.112205_b0060","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.112205_b0065","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-27.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"1","key":"10.1016\/j.diabres.2025.112205_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.diabres.2025.112205_b0075","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ckj\/sfac044","article-title":"A real-world study on SGLT2 inhibitors and diabetic kidney disease progression","volume":"15","author":"Liu","year":"2022","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.diabres.2025.112205_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14740\/jocmr3761","article-title":"Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b-4: A real world report from a Japanese specialized diabetes care center","volume":"11","author":"Sugiyama","year":"2019","journal-title":"J Clin Med Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112205_b0085","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/M23-1874","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease","volume":"177","author":"Yen","year":"2024","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.diabres.2025.112205_b0090","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"DAPA-CKD Trial Committees and Investigators; Members of the DAPA-CKD Trial Committees and Investigators. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor Dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.diabres.2025.112205_b0095","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: Post Hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2025.112205_b0100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pds.4713","article-title":"The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"19","key":"10.1016\/j.diabres.2025.112205_b0105","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112205_b0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 Inhibitors in heart failure: A review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"8","key":"10.1016\/j.diabres.2025.112205_b0115","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2025.112205_b0120","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.112205_b0125","volume":"48(Supplement_1):S181\u2013S206","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.112205_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c Levels","volume":"183","author":"D'Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.diabres.2025.112205_b0135","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of Canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112205_b0140","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112205_b0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.diabres.2025.112205_b0150","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112205_b0155","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.kint.2017.06.030","article-title":"AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms","volume":"92","author":"He","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.diabres.2025.112205_b0160","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrneph.2015.3","article-title":"Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD","volume":"11","author":"Ferenbach","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112205_b0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.kint.2017.05.034","article-title":"The hallmarks of mitochondrial dysfunction in chronic kidney disease","volume":"92","author":"Galvan","year":"2017","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.diabres.2025.112205_b0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112205_b0175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.0000000000000218","article-title":"Long-term, real-world kidney outcomes with SGLT2i versus DPP4i in type 2 diabetes without cardiovascular or kidney disease","volume":"18","author":"Melzer Cohen","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2025.112205_b0180","doi-asserted-by":"crossref","unstructured":"EMPA-KIDNEY Collaborative Group. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. 2024;12(1):39-50. Erratum in: Lancet Diabetes Endocrinol. 2024;12(3):e16.","DOI":"10.1016\/S2213-8587(24)00033-0"},{"issue":"8","key":"10.1016\/j.diabres.2025.112205_b0185","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112205_b0190","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR Decline after SGLT2 Inhibitor Initiation: The tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"issue":"3","key":"10.1016\/j.diabres.2025.112205_b0195","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.diabres.2025.112205_b0200","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 Protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.diabres.2025.112205_b0205","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/cells10061457","article-title":"Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells","volume":"10","author":"Xu","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.diabres.2025.112205_b0210","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jdi.13952","article-title":"Cardiometabolic risk reductions in patients with type\u20092 diabetes mellitus newly treated with a sodium-glucose cotransporter\u20092 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan","volume":"14","author":"Kashiwagi","year":"2023","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.diabres.2025.112205_b0215","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/s12913-019-4738-1","article-title":"Effects of health-information-based diabetes shared care program participation on preventable hospitalizations in Taiwan","volume":"19","author":"Liang","year":"2019","journal-title":"BMC Health Serv Res"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:49:24Z","timestamp":1778388564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":43,"alternative-id":["S0168822725002190"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112205","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112205"}}